cCAM Biotherapeutics

Monoclonal Antibodies for Cancer Treatment

Acquired by Merck
Acquired Hod HaSharon, Israel Founded 2010
LinkedIn
Last updated 2026-06-18
Total raised
$8.0M
Last: 2012-09
Stage
Acquired
Founded
2010
Headcount
1-10
HQ
Hod HaSharon, Israel
Sector

About

cCAM Biotherapeutics is a preclinical-stage company focused on the discovery and development of novel immunotherapies to treat cancer. The company's lead product, CM-24, is a phase 1 monoclonal antibody that inhibits the immunosuppressive effect of CEAC AM1, leading to an enhanced anti-tumor immune response of T and NK cells. cCAM Biotherapeutics' activity has been fully integrated into Merck & Co. Inc.

Funding history · 1 round · $8.0M total

Q&A

What is cCAM Biotherapeutics' primary focus?
cCAM Biotherapeutics is a preclinical-stage company focused on the discovery and development of novel immunotherapies to treat cancer.
What is cCAM Biotherapeutics' lead product?
cCAM Biotherapeutics' lead product is CM-24, a phase 1 monoclonal antibody designed to inhibit the immunosuppressive effect of CEAC AM1, thereby enhancing the anti-tumor immune response of T and NK cells.
When was cCAM Biotherapeutics founded?
cCAM Biotherapeutics was founded in January 2010.
What is the current status of cCAM Biotherapeutics?
cCAM Biotherapeutics is currently inactive, having been acquired by Merck in July 2015, and its activity has been fully integrated into Merck & Co. Inc.
How much funding has cCAM Biotherapeutics raised in total?
cCAM Biotherapeutics has raised a total of $8,000,000 USD.
When was cCAM Biotherapeutics' last funding round and who were the investors?
cCAM Biotherapeutics' last funding round occurred in September 2012, with participation from Arkin Tech and OrbiMed
What is the employee count for cCAM Biotherapeutics?
cCAM Biotherapeutics has an employee count in the 1-10 range.
In which sector does cCAM Biotherapeutics operate?
cCAM Biotherapeutics operates in the Health Tech & Life Sciences, Pharma & Medical Biotechnology, and Drugs Discovery & Development sectors.

Sectors & technology

Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Tags

therapeuticscancerpharmaceuticalsimmunologytreatmentspharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

LinkedInlinkedin.com/company/6015961

Identifiers & details

Founded2010-1
Status reasonAcquired (Inactive) by Merck on Jul 2015 - closed due to acquisition

Acquisitions & public offerings

Acquired by Merck 2015-07

Radar intelligence

Patents

EPO4